why choose us

Course: Long-term Immunogenicity of BNT162b2 Vaccine in Patients With Solid Tumors

CME Credits: 1.00

Released: 2022-04-22

In a previous cohort study, administration of the BNT162b2 vaccine in patients with solid tumors demonstrated a favorable safety and efficacy profile following the second vaccination, although gradual immunogenicity was observed compared with the general population. We had previously demonstrated at 6 months postvaccination a steady decline in antibody titers and seropositivity rates among patients with solid tumors treated at a center in Haifa, Israel, that were comparable with the general population. Because of declined immunity, a booster dose had been recommended by medical authorities.


Educational Objective
To identify the key insights or developments described in this article


View Full Course